AbbVie and Bristol-Myers Squibb have announced a clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumours.
The companies will collaborate to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
A Phase 1b clinical study is underway that includes evaluating the potential of combining Opdivo, which is designed to alleviate immune suppression, with ABBV-399 to explore the tolerability and potential efficacy of the combination in subjects with advanced c-Met overexpressing NSCLC who failed one prior line of chemotherapy.
Dr Tom Hudson, vice president, oncology early discovery and development, AbbVie, said: “Therapeutic advances continue to be achieved every day and we are committed to exploring the potential of our investigational compounds with other approved treatments with the goal to deliver a significant impact to patients.”
Dr Fouad Namouni, Head of Development, Oncology, Bristol-Myers Squibb, added: “We look forward to continuing to partner our PD1 with AbbVie’s early- and late-stage assets as a possible treatment option for patients with lung cancer.”
AbbVie is the sponsor conducting the trial. Specific terms of the agreement were not disclosed.